FDA deputy commissioner resigns
Executive Summary
FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb will return to the American Enterprise Institute to work on health policy issues following his resignation from the agency effective Jan. 16. Gottlieb will reunite with Mark McClellan, the former head of FDA and CMS who joined an AEI/Brookings Institution collaborative center last month (1"The Pink Sheet" Oct. 23, 2006, In Brief). Gottlieb served as a senior advisor to McClellan at both agencies...
You may also be interested in...
Lutter to fill Gottlieb’s shoes
FDA Associate Commissioner for Policy and Planning Randall Lutter is appointed acting deputy commissioner for policy, the agency announces Dec. 21. Lutter will replace Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb, who is leaving the agency Jan. 15 (1"The Pink Sheet" Dec. 18, 2006, In Brief). Lutter joined FDA in 2003 as chief economist in the agency's Office of Planning...
McClellan to think tanks
Former CMS Administrator Mark McClellan joins the Center for Regulatory Studies, a collaborative program jointly sponsored by the American Enterprise Institute and the Brookings Institution, as a visiting senior fellow. In his joint appointment at the Washington, D.C.-based think tanks, he will work on "the next steps for how I can hopefully continue to have an impact on issues like...the future of Medicare," he says at a Medicare conference sponsored by Avalere in Washington, D.C. Oct. 16. McClellan, who left CMS Oct. 14 after two years as administrator, says he will also continue his academic affiliation with Stanford University. McClellan has been succeeded at CMS by Acting Administrator Leslie Norwalk (1"The Pink Sheet" Sept. 11, 2006, p. 10)...
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.